SynthesisMedicine2020
Systemic sclerosis and risk of cardiovascular disease: A PRISMA-compliant systemic review and meta-analysis of cohort studies.
Synthesis in Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Ocular markers of microangiopathy and their possible association with cardiovascular risk in patients with systemic inflammatory rheumatic diseases: a systematic review.Frontiers in immunology · 2025Pooled it
- Association between systemic sclerosis and risk of cerebrovascular and cardiovascular disease: a meta-analysis.Scientific reports · 2024Pooled it
- Assessment of markers of primary aldosteronism in systemic sclerosis and their relationships with renal and cardiovascular outcomes.RMD open · 2026Article
- Sodium Glucose Co-Transporter-2 inhibitors in patients with systemic sclerosis with or without heart failure.The American journal of medicine · 2026Article
- Arrhythmias in Systemic Sclerosis: A Call for Interdisciplinarity Teams.Life (Basel, Switzerland) · 2025Review
- Proton pump inhibitors in systemic sclerosis: should we exercise caution? Insights from a large-scale data analysis.Clinical rheumatology · 2025Observational
- Endothelial function and vascular events in patients with limited cutaneous systemic sclerosis (EFVELSS): a prospective observational study.Rheumatology international · 2025Observational
- Noninvasive left ventricular myocardial work identifies subclinical myocardial dysfunction in patients with systemic sclerosis.Clinical rheumatology · 2025Article
- Acute Coronary Syndrome and Rheumatic Disease.Journal of clinical medicine · 2025Review
- Quantification of coronary artery calcification in systemic sclerosis using visual ordinal and deep learning scoring: Association with systemic sclerosis clinical features.Seminars in arthritis and rheumatism · 2025Article
- Residual Traditional Risk in Non-Traditional Atherosclerotic Diseases.International journal of molecular sciences · 2025Review
- Role of cognitive impairment and malnutrition as determinants of quality of life in patients with systemic sclerosis.Journal of scleroderma and related disorders · 2024Article
- Chronic low-grade inflammation in patients with systemic sclerosis is associated with increased risk for arteriosclerotic cardiovascular disease.Frontiers in medicine · 2024Article
- Plasma Dephosphorylated-Uncarboxylated Matrix Gla-Protein in Systemic Sclerosis Patients: Biomarker Potential for Vascular Calcification and Inflammation.Diagnostics (Basel, Switzerland) · 2023Article
- Arterial Stiffness as a Surrogate Marker of Cardiovascular Disease and Atherosclerosis in Patients with Arthritides and Connective Tissue Diseases: A Literature Review.Diagnostics (Basel, Switzerland) · 2023Review
- The Involvement of Smooth Muscle, Striated Muscle, and the Myocardium in Scleroderma: A Review.International journal of molecular sciences · 2022Review
- Lipid Alterations in Systemic Sclerosis.Frontiers in molecular biosciences · 2021Review
- Association Between Uric Acid and Worsening Peripheral Microangiopathy in Systemic Sclerosis.Frontiers in medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSystemic sclerosis (SSc) is an autoimmune disorder leading to extensive fibrosis and microvascular injury. Macrovascular disease is well documented in other autoimmune rheumatic diseases such as systemic lupus erythematosus and rheumatoid arthritis. However, the link is unclear between SSc and macrovascular disease, particularly atherosclerotic cardiovascular disease (CVD). This meta-analysis aimed to investigate the association between SSc and CVD.
methodsA thorough literature search was conducted in the Cochrane, Embase, Medline, and PubMed to identify all cohort studies comparing the risk of CVD with and without SSc. The pooled hazard ratios (HRs) with 95% confidence intervals (CIs) of cardiovascular end points were calculated. The risk of bias of included studies was assessed by the Newcastle-Ottawa scale.
resultsSeven cohort studies with a total of 14,813 study participants were included. In a comparison of SSc patients versus non-SSc controls, the pooled HR for cardiovascular disease was 2.36 (95% CI 1.97-2.81); for peripheral vascular disease was 5.27 (95%CI 4.27-6.51); for myocardial infarction was 2.36 (95% CI 1.71-3.25); and for stroke was 1.52 (95% CI 1.18-1.96).
conclusionThis meta-analysis revealed that SSc was associated with an increased risk of CVD. Clinicians who manage patients with SSc should be aware of the increased cardiovascular burden and undertake preventive measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.